Venture Capital

With new nostalgic flavors, key hires, and a powerful distribution network, Nixie is moving from natural food aisles to take on the conventional soda market.

Celebrating its 40th anniversary, the Ricordi® Chamber not only transformed diabetes research but now serves as the foundation for the future of cell therapy.

A new analysis shows security teams are drowning in alerts while attackers target a tiny fraction of bugs. This report redefines cyber risk prioritization.

A new exclusive deal pairs NeutronX's AI and federal access with NextNRG's energy tech, aiming to overhaul critical U.S. infrastructure and national security.

The well-funded mealtime innovator Wonder is betting big on Texas, promising thousands of jobs. But can its unique model conquer a crowded market?

Major outages are often caused by simple network config errors, not data loss. A new approach to disaster recovery targets this overlooked vulnerability.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Amid a volatile market, Rock Tech Lithium's latest funding from existing investors signals strong confidence in its strategy to build a local battery supply chain.

Amid growing parts shortages, SurplusGLOBAL's upgraded SemiMarket uses AI and a circular 'Harvest' model to keep aging but essential semiconductor lines running.

A new partnership tackles AI's hidden bottleneck, using advanced interconnects to boost AMD-powered cloud performance, reliability, and efficiency.

With $280M in new funding, Beijing's Spirit AI is using real-world 'dirty data' to build a universal robot brain, challenging Google and Tesla.

Destination marketing leader Digital Edge is now Go Fish Tourism + Business Events, integrating AI and expanded services to unify leisure and business travel promotion.

After a mixed earnings report, ScanSource's CFO will outline the firm's pivot to recurring revenue and converging tech at a key investor conference.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.